Chaudhary Lubna N, Wilkinson K Hope, Kong Amanda
Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Surg Oncol Clin N Am. 2018 Jan;27(1):141-153. doi: 10.1016/j.soc.2017.08.004.
Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer. Clinical research in the neoadjuvant setting is focused on improvement in pathologic complete response rates and outcomes of patients with residual disease.
三阴性乳腺癌的治疗进展仍然是一项重大挑战。鉴于其侵袭性生物学行为和远处复发的高风险，大多数患者需要进行全身化疗。新辅助化疗通过缩小肿瘤大小和增加保乳手术的可能性，使局部晚期疾病患者受益。临床和病理反应提供了重要的预后信息，这使得新辅助治疗成为所有三阴性乳腺癌患者的一种有吸引力的治疗方法。新辅助治疗环境下的临床研究主要集中在提高病理完全缓解率以及改善有残留病灶患者的治疗结果。
